3728-20-9

Basic information

• Product Name: H-D-TYR-OME HCL
• Synonyms: (R)-Methyl 2-aMino-3-(4-hydroxyphenyl)propanoate hydrochloride;H-D-Tyr-OMe hydrochloride;H-D-Tyr-OMe;D-Tyr-OMe·HCl;D-Tyrosine methyl ester hydrochloride≥ 98% (HPLC);D-TYROSINE ETHYL OME HCl;Methyl D-Tyrosinate Hydrochloride,99%e.e.;H-D-TYR-OME HCL
• CAS NO: 3728-20-9
• Molecular Formula: C₁₀H₁₄NO₃*Cl
• Molecular Weight: 231.68
• EINECS: 223-084-2
• Product Categories: Amino Acids and Derivatives;Amino hydrochloride;Amino Acid Derivatives
• Mol File: 3728-20-9.mol

Chemical Properties

• Melting Point: 177-179℃
• Boiling Point: 330 °C at 760 mmHg
• Flash Point: 153.4 °C
• Appearance: White to off-white/Powder
• Vapor Pressure: 8.89E-05mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: H-D-TYR-OME HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-TYR-OME HCL(3728-20-9)
• EPA Substance Registry System: H-D-TYR-OME HCL(3728-20-9)

Safety Data

• Hazardous Substances Data: 3728-20-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
H-D-TYR-OME HCL is used as an intermediate in the synthesis of oxybutynin chloride (O868525) for its inhibitory effects on proliferation and suppression of gene expression in bladder smooth muscle cells. This application aids in the development of treatments for conditions related to bladder smooth muscle overactivity.
Additionally, H-D-TYR-OME HCL may be utilized in other applications within the pharmaceutical industry, depending on its chemical properties and potential interactions with other compounds. Its crystalline nature could make it suitable for various drug formulations and delivery systems.

InChI:InChI=1/C10H13NO3.ClH/c1-14-10(13)9(11)6-7-2-4-8(12)5-3-7;/h2-5,9,12H,6,11H2,1H3;1H/t9-;/m1./s1

Upstream product

• 67-56-1 methanol 
• 556-02-5 tyrosine 
• 556-02-5 ?Tyr 
• 3417-91-2 tyrosine methyl ester hydrochloride 
• 60-18-4 L-tyrosine 
• 142847-18-5 N-(tert-butoxycarbonyl)tyrosine 

Downstream Products

• 3978-80-1 Boc-Tyr-OH 
• 70642-86-3 N-(tert-butoxycarbonyl)-D-tyrosine 
• 188576-13-8 methyl 2-[(t-butoxycarbonyl)amino]-3-(4-hydroxyphenyl)propanoate 
• 1172-65-2 2-(2-tert-Butoxycarbonylamino-3-hydroxy-propionylamino)-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 79397-31-2 2-[2-(4-Chloro-phenoxy)-acetylamino]-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 97654-03-0 Mal-Pab-Tyr-OMe 
• 101469-25-4 tyrosinamide 
• 69955-04-0 2-benzylideneamino-3-(4-hydroxyphenyl)-propionic acid methyl ester 
• 137957-18-7 2-(5,5-Dimethyl-3-oxo-cyclohex-1-enylamino)-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 556-02-5 tyrosine 
• 3410-66-0 D-tyrosine methyl ester 
• 60-18-4 L-tyrosine 
• 500-88-9 (+/-)-2-amino-3-(4-hydroxyphenyl)-1-propanol 
• 97485-13-7 2-benzamido-3-(4-(benzoyloxy)phenyl)propanoic acid 

Relevant articles and documents

(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative as well as preparation method and application thereof

The invention discloses a (2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative shown as a formula (I) or an optical isomer, a diastereomer and racemate mixture and pharmaceutically acceptable salt thereof as well as a preparation method and application of the (2S, 3R)-3-amino-2-hydroxy-4-phenylbutyrylamide derivative. It is shown by comparison of results of a positive control group and a model group on lymphedema prevention experiments that the compound disclosed in the invention shows obvious anti-edema activity.

Nickel-catalyzed deallylation of aryl allyl ethers with hydrosilanes

An efficient and mild catalytic deallylation method of aryl allyl ethers is developed, with commercially available Ni(COD)2 as catalyst precursor, simple substituted bipyridine as ligand and air-stable hydrosilanes. The process is compatible with a variety of functional groups and the desired phenol products can be obtained with excellent yields and selectivity. Besides, by detection or isolation of key intermediates, mechanism studies confirm that the deallylation undergoes η3-allylnickel intermediate pathway.

NovelN-transfer reagent for converting α-amino acid derivatives to α-diazo compounds

A novel universalN-transfer reagent for direct and effective transformation of α-amino ketones, acetamides, and esters to the corresponding α-diazo products under mild basic conditions has been developed. This one-step synthetic approach not only allows for generation of α-substituted-α-diazo carbonyl compounds from α-amino acid derivatives but also permits preparation of α-diazo dipeptides fromN-terminal dipeptides (32 examples, up to 91%).

N-transfer reagent and method for preparing the same and its application

Provided are a novel N-transfer reagent and a method for preparing the same and its application. The N-transfer reagent is represented by the following Formula (I): The various novel N-transfer reagents of the present invention can be quickly prepared by employing different nitrobenzene precursors. The N-transfer reagents can directly convert a variety of amino compounds into diazo compounds under mild conditions. Particularly, the N-transfer reagents can facilitate the synthesis of the diazo compounds. The application of synthesizing diazo compounds of the present invention can greatly decrease the difficulty in operation, increase the safety during experiments, reduce the cost of production and the environmental pollution, and enhance the industrial value of diazo compounds.

Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors

The NLRP3 inflammasome is a component of the innate immune system involved in the production of proinflammatory cytokines. Aberrant activation by a wide range of exogenous and endogenous signals can lead to chronic, low-grade inflammation. It has attracted a great deal of interest as a drug target due to the association with diseases of large unmet medical need such as Alzheimer's disease, Parkinson's disease, arthritis, and cancer. To date, no drugs specifically targeting inhibition of the NLRP3 inflammasome have been approved. In this work, we used the known NLRP3 inflammasome inhibitor CP-456,773 (aka CRID3 or MCC 950) as our starting point and undertook a Structure-Activity Relationship (SAR) analysis and subsequent scaffold-hopping exercise. This resulted in the rational design of a series of novel ester-substituted urea compounds that are highly potent and selective NLRP3 inflammasome inhibitors, as exemplified by compounds 44 and 45. It is hypothesized that the ester moiety acts as a highly permeable delivery vehicle and is subsequently hydrolyzed to the carboxylic acid active species by carboxylesterase enzymes. These molecules are greatly differentiated from the state-of-the-art and offer potential in the treatment of NLRP3-driven diseases, particularly where tissue penetration is required.

NOVEL TRF1 MODULATORS AND ANALOGUES THEREOF

Novel TRF1 modulators and analogues thereof. There is provided compounds of Formula I, wherein R, R1, R2 and X have meanings written in the description. Such compounds are useful as TRF1 inhibitors and, for that reason, as medicaments, in the treatment of cancer, particularly high cancer stem cell cancer like glioblastoma and lung cancer, and can be also useful for the development of additional TRF1 inhibitors and increasing knowledge about TRF1 activity.

Total Synthesis of Herquline B and C

The total syntheses of (-)-herquline B (2) and a heretofore-unrecognized congener, (+)-herquline C (3), are described. The syntheses require 14 and 13 steps, respectively, and feature a key oxazoline reduction that sets the stage for piperazine construction.

((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies

The emergence and global spread of metallo-β-lactamase (MBL) mediated resistance to almost all β-lactam antibacterials poses a serious threat to public health. Since no clinically useful MBL inhibitors have been reported, there is an urgent need to develop new potent broad-spectrum MBL inhibitors effective against antibacterial resistance. Herein, we synthesized a set of 2-substituted ((S)-3-mercapto-2-methylpropanamido) acetic acid derivatives, some of which displayed potent inhibition with high ligand efficiency to the clinically relevant MBL subtypes, Verona Integron-encoded MBL (VIM)-2 and New Delhi MBL (NDM)-1. Kinetic studies revealed that the inhibitors are not strong zinc chelators in solution, and they bind reversibly to VIM-2 but dissociate very slowly. Crystallographic analyses revealed that they inhibit VIM-2 via chelating the active site zinc ions and interacting with catalytically important residues. Further cell- and zebrafish-based assays revealed that the inhibitors slightly increase susceptibility of E. coli cells expressing VIM-2 to meropenem, and they have no apparent toxicity to the viability of HEK293T cells and the zebrafish embryogenesis.

Synthesis, in vitro antimicrobial, antioxidant, and antidiabetic activities of thiazolidine–quinoxaline derivatives with amino acid side chains

Abstract: A novel protocol for the rapid assembly of a hybrid framework based on amino acid, thiazolidine and quinoxaline scaffolds has been demonstrated by microwave irradiation. The quinoxalines with amino acid side chains 5a–5c were prepared in three steps from 2,4-dinitrofluorobenzene and the amino acids, valine, methionine, and tyrosine and subsequently reacted with four different aldehydes and thioglycolic acid to produce thiazolidine–quinoxaline hybrids with amino acid side chains 6a–6l. All synthesized compounds were evaluated for their in vitro antimicrobial, antioxidant, and antidiabetic activities. Compounds 6f, 6j, and 6k showed broad spectrum antimicrobial activity against Gram +ve and Gram –ve bacteria, whilst 6h, 6k, and 6l showed the best antioxidant activity in the same order of magnitude to that of ascorbic acid. Four of the compounds, 5c, 6d, 6g, and 6k showed activity against α-glucosidase and α-amylase similar to acarbose. Those compounds showing antibacterial activity possessed 4-fluorophenyl and 4-methoxyphenyl groups along with methionine and tyrosine side chains while the compounds showing antioxidant, α-glucosidase, and α-amylase activity contained 4-nitrophenyl and 4-methoxyphenyl groups on the thiazolidine moiety with mainly methionine and tyrosine side chains. The α-glucosidase and α-amylase inhibitory compound 5c did not have a thiazolidine moiety and 6d was the only active compound with a valine amino acid side chain. Compound 6k with a tyrosine side chain and a 4-methoxyphenylthiazolidine moiety on the quinoxaline scaffold showed good bioactivity in all three assays.

Ferrocene-modified amino acids: synthesis and in vivo bioeffects on hippocampus

A method for the ferrocene modification of amino acids of natural and synthetic origin has been developed. In the in vivo studies, the hippocampal electrical activity under the action of ferrocenyl(phenylpyrazolyl)glycine (1) was assessed. A meaningful rise (up to 25% compared to the control) in the response amplitudes of the focal potentials of the hippocampal region СА1 after intraperitoneal administration of compound 1 at the dose of 2.0 mg kg–1 was established.